Bimodal induction of dopamine-mediated striatal neurotoxicity is mediated through both activation of D1 dopamine receptors and autoxidation

Molecular and Cellular Neuroscience

Volumn 25, Issue 1, 2004, Pages 124-137

  Wersinger, Christophe ^a   Chen, Jun ^a   Sidhu, Anita ^a,b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,3,4,5 TETRAHYDRO 7,8 DIHYDROXY 1 PHENYL 1H 3 BENZAZEPINE; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; ANTIOXIDANT; BETA ADRENERGIC RECEPTOR; CYCLIC AMP DEPENDENT PROTEIN KINASE INHIBITOR; CYCLIC AMP DERIVATIVE; DOPAMINE; DOPAMINE 1 RECEPTOR; DOPAMINE 1 RECEPTOR BLOCKING AGENT; DOPAMINE 1 RECEPTOR STIMULATING AGENT; DOPAMINE 2 RECEPTOR; FREE RADICAL; HYDROGEN PEROXIDE; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; SODIUM METABISULFITE;

ANIMAL CELL; ANIMAL MODEL; ARTICLE; AUTOOXIDATION; CONTROLLED STUDY; DOPAMINERGIC SYSTEM; EMBRYO; ENZYME ACTIVATION; ENZYME SYNTHESIS; NERVE CELL; NERVE CELL CULTURE; NERVE CELL NECROSIS; NEUROPROTECTION; NEUROTOXICITY; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; PRIORITY JOURNAL; RAT; RECEPTOR BLOCKING; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; STRIATONIGRAL DEGENERATION;

EID: 1242316257     PISSN: 10447431     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcn.2003.10.002     Document Type: Article

References (63)

1. Alderton W.K., Cooper C.E., Knowles R.G. Nitric oxide synthases: structure, function and inhibition. Biochem. J. 357:2001;593-615.
2. Andringa G., Lubbers L., Drukarch B., Stoof J.C., Cools A.R. The predictive validity of the drug-naïve bilaterally MPTP-treated monkey as a model of Parkinson's disease: effects of L-DOPA and the D1 agonist SKF 82958. Behav. Pharmacol. 10(2):1999;175-182.
3. Andringa G., Stoof J.C., Cools A.R. Sub-chronic administration of the dopamine D(1) antagonist SKF 83959 in bilaterally MPTP-treated rhesus monkeys: stable therapeutic effects and wearing-off dyskinesia. Psychopharmacology. 146(3):1999;328-334.
4. Ayata C., Ayata G., Hara H., Matthews R.T., Beal M.F., Ferrante R.J., Endres M., Kim A., Christie R.H., Waeber C., Huang P.L., Hyman B.T., Moskowitz M.A. Mechanisms of reduced striatal NMDA excitotoxicity in type I nitric oxide synthase knock-out mice. J. Neurosci. 17(18):1997;6908-6917.
5. Bazzett T., Geiger A., Coppola B., Albin R. The neuronal NOS inhibitor L-MIN, but not 7-NINA, reduces neurotoxic effects of chronic intrastriatal administration of quinolinic acid. Brain Res. 775(1-2):1997;229-232.
6. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog. Neurobiol. 65:2001;135-172.
7. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
8. Bredt D.S. Endogenous nitric oxide synthesis: biological functions and pathophysiology. Free Radic. Res. 31(6):1999;577-596.
9. Brewer G.J., Torricelli J.R., Evege E.K., Price P.J. Optimized survival of hippocampal neurons in B27-supplemented Neurobasal, a new serum-free medium combination. J. Neurosci. Res. 35:1993;567-576.
10. Calabresi P., Centonze D., Gubellini P., Marfia G.A., Pisani A., Sancesario G., Bernardi G. Synaptic transmission in the striatum: from plasticity to neurodegeneration. Prog. Neurobiol. 61:2000;231-265.
11. Caron M.G. Transporter mediated regulation of neural communication. J. Neurochem. 85(Suppl. 2):2003;2.
12. Chen N.H., Reith M.E. In vivo microdialysis for measurement of extracellular monoamine levels following inhibition of monoamine transporters. Methods Enzymol. 296:1998;719-730.
13. Chen J., Wersinger C., Sidhu A. Chronic stimulation of D1 dopamine receptors in human SK-N-MC neuroblastoma cells induces nitric oxide synthase activation and cytotoxicity. J. Biol. Chem. 278(30):2003;28089-28100.
14. Coleman J.W. Nitric oxide: a regulator of mast cell activation and mast cell-mediated inflammation. Clin. Exp. Immunol. 129:2002;4-10.
15. Cyr M., Beaulieu J.M., Laakso A., Sotnikova T.D., Yao W.D., Bohn L.M., Gainetdinov R.R., Caron M.G. Sustained elevation of extracellular dopamine causes motor dysfunction and selective degeneration of striatal GABAergic neurons. Proc. Natl. Acad. Sci. U. S. A. 100(19):2003;11035-11040.
16. Deckel A.W. Nitric oxide and nitric oxide synthase in Huntington's disease. J. Neurosci. Res. 64(2):2001;99-107.
17. Deckel A.W., Tang V., Nuttal D., Gary K., Elder R. Altered neuronal nitric oxide synthase expression contributes to disease progression in Huntington's disease transgenic mice. Brain Res. 939(1-2):2002;76-86.
18. Deng X., Cadet J.L. Methamphetamine administration causes overexpression of nNOS in the mouse striatum. Brain Res. 851(1-2):1999;254-257.
19. Demchyshyn L.L., O'Dowd B.F., George S.R. Structure of mammalian D1 and D5 dopamine receptors and their function and regulation in cells. Sidhu A., Laruelle M., Vernier P. Dopamine Receptors and Transporters - Function, Imaging, and Clinical Implication. 2003;45-76 Marcel Dekker, New York.
20. Drago J., Padungchaichot P., Wong J.Y., Lawrence A.J., McManus J.F., Sumarsono S.H., Natoli A.L., Lakso M., Wreford N., Westphal H., Kola I., Finkelstein D.I. Targeted expression of a toxin gene to D1 dopamine receptor neurons by Cre-mediated site-specific recombination. J. Neurosci. 18:1998;9845-9857.
21. Foley T.D. The cyclooxygenase hydroperoxide product PGG(2) activates synaptic nitric oxide synthase: a possible antioxidant response to membrane lipid peroxidation. Biochem. Biophys. Res. Commun. 286(2):2001;235-238.
22. Gainetdinov R.R., Bohn L.M., Caron M.G. Neurochemistry and pharmacology of the dopamine system in mice lacking vesicular and plasma membrane uptake mechanisms. Sidhu A., Laruelle M., Vernier P. Dopamine Receptors and Transporters - Function, Imaging, and Clinical Implication. 2003;565-592 Marcel Dekker, New York.
23. Ghorayeb I., Fernagut P.O., Aubert I., Bezard E., Poewe W., Wenning G.K., Tison F. Toward a primate model of L-dopa-unresponsive parkinsonism mimicking striatonigral degeneration. Mov. Disord. 15:2000;531-536.
24. Hantraye P. Modeling dopamine system dysfunction in experimental animals. Nucl. Med. Biol. 25:1998;721-728.
25. Jackson A., Iwasiow R.M., Chaar Z.Y., Nantel M.F., Tiberi M. Homologous regulation of the heptahelical D1A receptor responsiveness: specific cytoplasmic tail regions mediate dopamine-induced phosphorylation, desensitization and endocytosis. J. Neurochem. 82:2002;683-697.
26. Jones S.R., Gainetdinov R.R., Wightman R.M., Caron M.G. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J. Neurosci. 18(6):1998;1979-1986.
27. Keinanen R., Vartiainen N., Koistinaho J. Molecular cloning and characterization of the rat inducible nitric oxide synthase (iNOS) gene. Gene. 234:1999;297-305.
28. Kim O.J., Ariano M.A., Lazzarini R.A., Levine M.S., Sibley D.R. Neurofilament-M interacts with the D1 dopamine receptor to regulate cell surface expression and desensitization. J. Neurosci. 22:2002;5920-5930.
29. Kimura K., White B.H., Sidhu A. Coupling of human D-1 dopamine receptors to different guanine nucleotide binding proteins. Evidence that D-1 dopamine receptors can couple to both Gs and G(o). J. Biol. Chem. 270(24):1995;14672- 14678.
30. Koutsilieri E., Scheller C., Grunblatt E., Nara K., Li J., Riederer P. Free radicals in Parkinson's disease. J. Neurol. 249:2002;S1-S5.
31. Lachowicz J.E., Sibley D.R. Dopaminergic receptor function defined by studying genetically altered mice. Sidhu A., Laruelle M., Vernier P. Dopamine Receptors and Transporters - Function, Imaging, and Clinical Implication. 2003;295-320 Marcel Dekker, New York.
32. Lecanu L., Verrecchia C., Margaill I., Boulu R.G., Plotkine M. iNOS contribution to the NMDA-induced excitotoxic lesion in the rat striatum. Br. J. Pharmacol. 125(3):1998;584-590.
33. Lecanu L., Margaill I., Boughali H., Cohen-Tenoudji B., Boulu R.G., Plotkine M. Deleterious Ca-independent NOS activity after oxidative stress in rat striatum. NeuroReport. 9(3):1998;559-563.
34. Lewis M.M., Watts V.J., Lawler C.P., Nichols D.E., Mailman R.B. Homologous desensitization of the D1A dopamine receptor: efficacy in causing desensitization dissociates from both receptor occupancy and functional potency. J. Pharmacol. Exp. Ther. 286:1998;345-353.
35. Liberatore G.T., Jackson-Lewis V., Vukosavic S., Mandir A.S., Vila M., McAulife W.G., Dawson V.L., Dawson T.M., Przedborski S. Inducible nitric oxide synthase stimulates dopaminergic neurodegeneration in the MPTP-model of Parkinson disease. Nat. Med. 5:1999;1403-1409.
36. Mendes A.F., Caramona M.M., Carvalho A.P., Lopes M.C. Differential roles of hydrogen peroxide and superoxide in mediating Il-1-induced NF-kappaB activation and iNOS expression in bovine articular chondrocytes. J. Cell. Biochem. 88(4):2003;783-793.
37. Morris B.J., Simpson C.S., Mundell S., Maceachern K., Johnston H.M., Nolan A.M. Dynamic changes in NADPH-diaphorase staining reflect activity of nitric oxide synthase: evidence for a dopaminergic regulation of striatal nitric oxide release. Neuropharmacology. 36(11-12):1997;1589-1599.
38. Nagatsu T. Parkinson's disease: changes in apoptosis-related factors suggesting possible gene therapy. J. Neural Transm. 109:2002;732-745.
39. Nelson N. The family of Na+/Cl- neurotransmitter transporters. J. Neurochem. 71:1998;1785-1803.
40. Ng G.Y., Mouillac B., George S.R., Caron M., Dennis M., Bouvier M., O'Dowd B.F. Desensitization, phosphorylation and palmitoyaltion of the human D1 receptor. Eur. J. Pharmacol. 267:1994;7-19.
41. Nishino H., Fujimoto I., Shimano Y., Hida H., Kumazaki M., Fukuda A. 3-Nitropropionic acid produces striatum selective lesions accompanied by iNOS expression. J. Chem. Neuroanat. 10(3-4):1996;209-212.
42. Park M.H., Park E.H. Synaptic concentration of dopamine in rat striatal slices in relationship to [3H]raclopride binding to the dopamine D2 receptor. Arch. Pharm. Res. 23(4):2000;360-366.
43. Perez-Severiano F., Escalante B., Vergara P., Rios C., Segovia J. Age-dependent changes in nitric oxide synthase activity and protein expression in striata of mice transgenic for the Huntington's disease mutation. Brain Res. 951(1):2002;36-42.
44. Prou D., Gu W.J., Le Crom S., Vincent J.D., Salamero J., Vernier P. Intracellular retention of the two isoforms of the D(2) dopamine receptor promotes endoplasmic reticulum disruption. J. Cell Sci. 114:2001;3517-3527.
45. Przedborski S., Jackson-Lewis V., Yokoyama R., Shibata T., Dawson V.L., Dawson T.M. Role of neuronal nitric oxide in 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP)-induced dopaminergic neurotoxicity. Proc. Natl. Acad. Sci. U. S. A. 93:1996;4565-4571.
46. Rao K.M. Molecular mechanisms regulating iNOS expression in various cell types. J. Toxicol. Environ. Health, Part B. Crit. Rev. 3:2000;27-58.
47. Shin Y., White B.H., Uh M., Sidhu A. Modulation of D1-like dopamine receptor function by aldehydic products of lipid peroxidation. Brain Res. 968(1):2003;102-113.
48. Sibley D.R. New insights into dopaminergic receptor function using antisense and genetically altered animals. Annu. Rev. Pharmacol. Toxicol. 288:1999;421-427.
49. Sidhu A., Fishman P.H. Identification and characterization of functional D1 dopamine receptors in a human neuroblastoma cell line. Biochem. Biophys. Res. Commun. 166(2):1990;574-579.
50. Sidhu A., Kimura K. A novel regulation of expression of the alpha-subunit of the G-stimulatory protein by dopamine via D1 dopamine receptors. J. Neurochem. 68:1997;187-194.
51. Sidhu A., Niznik H.B. Coupling of dopamine receptor subtypes to multiple and diverse G proteins. Int. J. Dev. Neurosci. 18:2000;669-677.
52. Sidhu A., Olde B., Humblot N., Kimura K., Gardner N. Regulation of human D1 dopamine receptor function and gene expression in SK-N-MC neuroblastoma cells. Neuroscience. 91:1999;537-547.
53. Spielewoy C., Giros B. Recent advances in the molecular mechanisms of psychostimulant abuse by using knock out mice. Sidhu A., Laruelle M., Vernier P. Dopamine Receptors and Transporters - Function, Imaging, and Clinical Implication. 2003;529-564 Marcel Dekker, New York.
54. Steiner H., Kitai S.T. Regulation of rat cortex function by D1 dopamine receptors in the striatum. J. Neurosci. 20:2000;5449-5460.
55. Stephans S., Yamamoto B. Methamphetamine pretreatment and the vulnerability of the striatum to metamphetamine neurotoxicity. Neuroscience. 72:1996;593-600.
56. Tabrizi S.J., Workman J., Hart P.E., Mangiarini L., Mahal A., Bates G., Cooper J.M., Schapira A.H. Mitochondrial dysfunction and free radical damage in the Huntington R6/2 transgenic mouse. Ann. Neurol. 47(1):2000;80-86.
57. Wang J.Q., Lau Y.S. Dose-related alteration in nitric oxide synthase mRNA expression induced by amphetamine and the full D1 receptor agonist SKF-82958 in mouse striatum. Neurosci. Lett. 311:2001;5-8.
58. Wang Y.M., Gainetdinov R.R., Fumagalli F., Xu F., Jones S.R., Bock C.B., Miller G.W., Wightman R.M., Caron M.G. Knock-out of the vesicular monoamine transporter 2 gene results in neonatal death and supersensitivity to cocaine and amphetamine. Neuron. 19(6):1997;1285-1296.
59. Wersinger C., Sidhu A. Inflammation and Parkinson's disease. Curr. Drug Targets. Inflamm. Allergy. 1:2002;221-242.
60. Wersinger C., White B.H., Senogles S.E., Sidhu A. Physiology, pharmacology, and pathophysiology of the D1-like family of dopamine receptors in the central nervous system. Sidhu A., Laruelle M., Vernier P. Dopamine Receptors and Transporters - Function, Imaging, and Clinical Implication. 2003;145-210 Marcel Dekker, New York.
61. Wersinger, C., Prou, D., Vernier, P., Sidhu, A., 2003b. Modulation of dopamine transporter function by a-synuclein is altered by impairment of cell adhesion and by induction of oxidative stress. FASEB J. September 4 [Epub ahead of print] FASEB J. express article 10.1096/fj.03-0152fje.
62. Wiesinger H. Arginine metabolism and the synthesis of nitric oxide in the nervous system. Prog. Neurobiol. 64(4):2001;365-391.
63. Yurochko A.D., Hwang E.S., Rasmussen L., Keay S., Pereira L., Huang E.S. The human cytomegalovirus UL55 (gB) and UL75 (gH) glycoprotein ligands initiate the rapid activation of Sp1 and NF-kappaB during infection. J. Virol. 71:1997;5051-5059.